Vanguard Fiduciary Trust
NRIX icon

Vanguard Fiduciary Trust’s Nurix Therapeutics NRIX Stock Holding History

Vanguard Fiduciary Trust’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.7M Buy
686,338
+54,107
+9% +$922K ﹤0.01% 1551
2026
Q1 		$9.8M Buy
+632,231
New +$10.5M ﹤0.01% 1724

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust's NRIX Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Nurix Therapeutics (NRIX) stake by 8.6% in Q2 2026, buying an estimated $922K and bringing the position to 686,338 shares worth $16.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1551.

Vanguard Fiduciary Trust first reported a position in NRIX in Q1 2026 and has held it in 2 quarters since. 210 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Vanguard Fiduciary Trust held 686,338 shares of Nurix Therapeutics worth $16.7M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 54,107 Nurix Therapeutics shares in Q2 2026, an estimated $922K.
  • Nurix Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #1551 holding.
  • Vanguard Fiduciary Trust first reported a position in Nurix Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 210 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.